Pituitary adenylate cyclase-activating polypeptide: Protective effects in stroke and dementia
| Autor: | William A. Banks, Naoko Nonaka, Seiji Shioda |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
endocrine system
Physiology Central nervous system Adenylate kinase 030209 endocrinology & metabolism Disease Pharmacology Biochemistry Cyclase 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Endocrinology Alzheimer Disease Memory medicine Dementia Animals Humans Learning Stroke Regulation of gene expression biology business.industry medicine.disease medicine.anatomical_structure Neuroprotective Agents Blood-Brain Barrier biology.protein Pituitary Adenylate Cyclase-Activating Polypeptide business hormones hormone substitutes and hormone antagonists 030217 neurology & neurosurgery Neurotrophin |
| Zdroj: | Peptides. 130 |
| ISSN: | 1873-5169 |
| Popis: | Evidence shows that pituitary adenylate cyclase-activating polypeptide (PACAP) improves stroke outcomes and dementia. The blood-brain barrier (BBB) controls the peptide and regulatory protein exchange between the central nervous system and the blood; the transport of these regulatory substances across the BBB has been altered in animal models of stroke and Alzheimer's disease (AD). PACAP is a powerful neurotrophin that can cross the BBB, which may aid in the therapy of neurodegenerative diseases, including stroke and AD. PACAP may function as a potential drug in the treatment, prevention, or management of stroke and AD and other neurodegenerative conditions. Here, we review the effects of PACAP in studies on stroke and dementias. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect